Literature DB >> 11408360

Methadone inhibits rhodamine123 transport in Caco-2 cells.

E Störmer1, M D Perloff, L L von Moltke, D J Greenblatt.   

Abstract

This study investigated the effects of racemic methadone (MET) on P-glycoprotein (P-gp) activity in cell culture. MET showed no differential rates of passage between the basolateral to apical (B to A) and apical to basolateral (A to B) direction across Caco-2 cell monolayers in a transwell system. MET transport in either direction was not importantly influenced by the P-gp inhibitor verapamil. However, MET was a potent inhibitor (IC(50) = 7.5 microM) of rhodamine123 B to A transport across Caco-2 cell monolayers, causing a reduction to 25% of control at 100 microM MET. In this model of Caco-2 monolayers, rates of MET passage between B to A and A to B directions could not be distinguished. However, MET can inhibit P-gp activity at intraluminal concentrations that might be achieved clinically. This may lead to increased bioavailability of coadministered compounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408360

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 2.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

Review 4.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  A Conformationally Gated Model of Methadone and Loperamide Transport by P-Glycoprotein.

Authors:  Morgan E Gibbs; Laura A Wilt; Kaitlyn V Ledwitch; Arthur G Roberts
Journal:  J Pharm Sci       Date:  2018-02-28       Impact factor: 3.534

7.  Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.

Authors:  Stéphane Mouly; Vanessa Bloch; Katell Peoc'h; Pascal Houze; Laurence Labat; Kamilia Ksouda; Guy Simoneau; Xavier Declèves; Jean Francois Bergmann; Jean-Michel Scherrmann; Jean-Louis Laplanche; Jean-Pierre Lepine; Florence Vorspan
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

8.  Alcohol and Cocaine Exposure Modulates ABCB1 and ABCG2 Transporters in Male Alcohol-Preferring Rats.

Authors:  Alaa M Hammad; Fawaz Alasmari; Youssef Sari; F Scott Hall; Amit K Tiwari
Journal:  Mol Neurobiol       Date:  2018-07-06       Impact factor: 5.590

Review 9.  Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

Authors:  Dhananjay Pal; Deep Kwatra; Mukul Minocha; Durga K Paturi; Balasubrahmanyam Budda; Ashim K Mitra
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 5.037

10.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.